Opium (Opioid) Addiction-Pipeline Review, H1 2017

Opium (Opioid) Addiction-Pipeline Review, H1 2017


  • Products Id :- GMDHC9170IDB
  • |
  • Pages: 104
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Opium (Opioid) Addiction-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction-Pipeline Review, H1 2017, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 2, 4, 2, 13 and 3 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).

The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)

Reasons to Buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Opium (Opioid) Addiction-Overview 6

Opium (Opioid) Addiction-Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Pipeline by Universities/Institutes 11

Products under Development by Companies 12

Products under Development by Universities/Institutes 14

Opium (Opioid) Addiction-Therapeutics Assessment 15

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Opium (Opioid) Addiction-Companies Involved in Therapeutics Development 23

Alkermes Plc 23

Aoxing Pharmaceutical Company Inc 23

Aquilus Pharmaceuticals Inc 24

BioCorRx Inc 24

BioDelivery Sciences International Inc 25

Camurus AB 25

Foresee Pharmaceuticals LLC 26

Heron Therapeutics Inc 26

Indivior Plc 27

INSYS Therapeutics Inc 28

Omeros Corp 29

Opiant Pharmaceuticals Inc 29

Orexigen Therapeutics Inc 30

Orexo AB 30

Pfizer Inc 31

Relmada Therapeutics Inc 31

Savant HWP Inc 32

Teva Pharmaceutical Industries Ltd 32

Titan Pharmaceuticals Inc 33

Zynerba Pharmaceuticals Inc 33

Opium (Opioid) Addiction-Drug Profiles 34

(buprenorphine hydrochloride + naloxone hydrochloride)-Drug Profile 34

(buprenorphine hydrochloride + naloxone hydrochloride)-Drug Profile 35

(buprenorphine hydrochloride + naloxone hydrochloride)-Drug Profile 36

(buprenorphine hydrochloride + naloxone hydrochloride)-Drug Profile 37

(buprenorphine hydrochloride + samidorphan l-malate)-Drug Profile 38

18-MC-Drug Profile 44

AQU-010-Drug Profile 46

buprenorphine hydrochloride-Drug Profile 47

buprenorphine hydrochloride-Drug Profile 50

buprenorphine hydrochloride-Drug Profile 51

buprenorphine hydrochloride depot-Drug Profile 56

buprenorphine hydrochloride ER-Drug Profile 57

buprenorphine hydrochloride long acting-Drug Profile 59

buprenorphine hydrochloride SR-Drug Profile 60

cannabidiol-Drug Profile 63

cannabidiol-Drug Profile 64

Canquit-O-Drug Profile 67

FP-004-Drug Profile 68

naltrexone hydrochloride-Drug Profile 69

naltrexone hydrochloride-Drug Profile 70

naltrexone hydrochloride SR-Drug Profile 71

OMS-405-Drug Profile 73

OMS-527-Drug Profile 75

OREX-1019-Drug Profile 77

ORP-107-Drug Profile 78

PF-4363467-Drug Profile 79

PF-5006739-Drug Profile 80

Small Molecule to Antagonize D3 Receptor for Opioid Addiction-Drug Profile 81

TEV-90109-Drug Profile 82

Vaccine for Opioid Addiction-Drug Profile 83

Vaccine for Opium Addiction-Drug Profile 84

Opium (Opioid) Addiction-Dormant Projects 85

Opium (Opioid) Addiction-Discontinued Products 86

Opium (Opioid) Addiction-Product Development Milestones 87

Featured News & Press Releases 87

Appendix 100

Methodology 100

Coverage 100

Secondary Research 100

Primary Research 100

Expert Panel Validation 100

Contact Us 100

Disclaimer 101

List of Figures

Number of Products under Development for Opium (Opioid) Addiction, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Opium (Opioid) Addiction, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Opium (Opioid) Addiction-Pipeline by Alkermes Plc, H1 2017

Opium (Opioid) Addiction-Pipeline by Aoxing Pharmaceutical Company Inc, H1 2017

Opium (Opioid) Addiction-Pipeline by Aquilus Pharmaceuticals Inc, H1 2017

Opium (Opioid) Addiction-Pipeline by BioCorRx Inc, H1 2017

Opium (Opioid) Addiction-Pipeline by BioDelivery Sciences International Inc, H1 2017

Opium (Opioid) Addiction-Pipeline by Camurus AB, H1 2017

Opium (Opioid) Addiction-Pipeline by Foresee Pharmaceuticals LLC, H1 2017

Opium (Opioid) Addiction-Pipeline by Heron Therapeutics Inc, H1 2017

Opium (Opioid) Addiction-Pipeline by Indivior Plc, H1 2017

Opium (Opioid) Addiction-Pipeline by INSYS Therapeutics Inc, H1 2017

Opium (Opioid) Addiction-Pipeline by Omeros Corp, H1 2017

Opium (Opioid) Addiction-Pipeline by Opiant Pharmaceuticals Inc, H1 2017

Opium (Opioid) Addiction-Pipeline by Orexigen Therapeutics Inc, H1 2017

Opium (Opioid) Addiction-Pipeline by Orexo AB, H1 2017

Opium (Opioid) Addiction-Pipeline by Pfizer Inc, H1 2017

Opium (Opioid) Addiction-Pipeline by Relmada Therapeutics Inc, H1 2017

Opium (Opioid) Addiction-Pipeline by Savant HWP Inc, H1 2017

Opium (Opioid) Addiction-Pipeline by Teva Pharmaceutical Industries Ltd, H1 2017

Opium (Opioid) Addiction-Pipeline by Titan Pharmaceuticals Inc, H1 2017

Opium (Opioid) Addiction-Pipeline by Zynerba Pharmaceuticals Inc, H1 2017

Opium (Opioid) Addiction-Dormant Projects, H1 2017

Opium (Opioid) Addiction-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Alkermes Plc, Aoxing Pharmaceutical Company Inc, Aquilus Pharmaceuticals Inc, BioCorRx Inc, BioDelivery Sciences International Inc, Camurus AB, Foresee Pharmaceuticals LLC, Heron Therapeutics Inc, Indivior Plc, INSYS Therapeutics Inc, Omeros Corp, Opiant Pharmaceuticals Inc, Orexigen Therapeutics Inc, Orexo AB, Pfizer Inc, Relmada Therapeutics Inc, Savant HWP Inc, Teva Pharmaceutical Industries Ltd, Titan Pharmaceuticals Inc, Zynerba Pharmaceuticals Inc

select a license

Single User License
USD 2000 INR 129160
Site License
USD 4000 INR 258320
Corporate User License
USD 6000 INR 387480

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com